Skip to main content

Marine Bio-Technologies Board of Directors & Management

Board of Directors

Ann M. Borden, EOS Remediation, Solutions-IES
J. Barry Buzogany, T3D Therapeutics
Joseph S. Holmes, Acuity Edge, Inc. 
Michael J. McKenna, 
Navigator Life Science Advisory - Board Chair
E. Eric Mills, Nexsen Pruet, PLLC

Management Team

Deborah A. Mosca, Chief Executive Officer

Dr. Mosca (Deb) is the Chief Executive Officer of the Marine Bio-Technologies Center of Innovation, based at the Center for Marine Sciences in Wilmington, NC. She has 31 years of experience in biotech research and commercial organizations. Previously she served as the Vice President of Project Management at PaxVax, Inc. in San Diego, CA. There, she obtained $24 million in National Institutes of Health funding to develop an Anthrax vaccine and $9.5 million for an HIV vaccine. She has led seven multidisciplinary project teams focused on vaccine development. Prior to that, she served as the Senior Director of Business Development at The Scripps Research Institute in San Diego, where she was responsible for executing the business plan for Scripps Florida. Her duties included outlicensing technologies, negotiating terms for contracts and collaborations, and facilitating the development of new enterprises derived from scientific efforts at Scripps Florida. Dr. Mosca has also held positions as a research biologist, group leader for American Cyanamid Co., Senior Director of Microbiology for IntraBiotics Pharmaceuticals, Vice President of Drug Development for Elitra Pharmaceuticals, and Vice President for Research & Preclinical Development at Nereus Pharmaceuticals. Dr. Mosca obtained a B.S. in Genetics from Cornell University, and a Ph.D. in Biology from State University of New York, Buffalo.

Royston E. Carter, Senior Director for Marine BioTechnology Development

Dr. Carter (Roy) is the Senior Director for Development, based at the North Carolina State University Center for Marine and Science Technology (NCSU CMAST) in Morehead City, NC.  He has over 25 years of diverse life science R&D and technology commercialization experience. Most recently Roy worked as a consultant helping university TTO evaluate and commercialize new life science inventions, and private clients translate technology platforms into new business sectors. Previously, he was Director of Biochemistry at Biowarn LLC, a biosensor company focused on bioweapon detection. He established and led biology, chemistry and technology application teams before becoming its Chief Scientific Officer. He then co-founded Biohmics Inc. a start-up to apply the biosensor for point-of-care diagnostics. Prior he held a staff scientist and project leadership position at Novartis and Syngenta, initiating new projects in agricultural biotechnology for insect-resistant crops, animal feed and cellulosic biofuels. Roy completed two post-doctoral appointments related to molecular genetics & cell biology of cancer including development of novel live-cell imaging methods. He received an undergraduate degree in applied biochemistry from Liverpool Polytechnic (England) and earned his PhD in Genetics from the University of Nottingham (England), where he is recognized as an early pioneer in the development and application of DNA fingerprinting methodologies for use in ecological studies of wild birds and animals.